Quality of Life in People with Type 2 Diabetes on Metformin–Sitagliptin Combination Therapy: A Questionnaire-Based Cross-Sectional Study
Abstract
Background: Diabetes mellitus is a major public health challenge in India, contributing significantly to morbidity and reduced quality of life (QOL). Metformin remains the cornerstone of pharmacological therapy, while dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin are increasingly prescribed as add-on agents. Despite well-established efficacy and safety, evidence on QOL outcomes with this drug combination remains limited. This study assessed QOL in individuals with type 2 diabetes mellitus (T2DM) receiving metformin–sitagliptin therapy and explored the association between sitagliptin dose and QOL. Materials and Methods: A cross-sectional study was conducted among 80 adults with T2DM attending the Department of Endocrinology, Government Medical College, Thiruvananthapuram, and the Indian Institute of Diabetes, Pulayanarkotta. Eligible participants (≥18 years) on metformin (≥1000 mg) plus sitagliptin (50–100 mg) were recruited after informed consent. Baseline demographic, clinical, and laboratory details were documented. QOL was assessed at 12 weeks using the WHOQOL-BREF questionnaire in Malayalam or English. Domain scores were transformed to a 0–100 scale and classified as poor, intermediate, or good QOL. Results: The mean age of participants was 56 ± 9.06 years, with 60% male. Median scores in physical, psychological, social, and environmental domains indicated an overall moderate QOL. Participants receiving sitagliptin 100 mg demonstrated higher mean domain…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 80 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.